.Pharmacolibrary.Drugs.ATC.N.N04BD02

Information

Rasagiline is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor used as monotherapy or as adjunct therapy to levodopa in the treatment of Parkinson's disease. It is approved for use in many countries, including the US and EU.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers following single oral administration.

References

1. Zhou, W, et al., & Wang, M (2018). Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects. Clinical drug investigation 38(2) 125–133. DOI:10.1007/s40261-017-0588-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/29159774

2. Chen, X, et al., & Hu, P (2016). Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study. Clinical drug investigation 36(5) 369–376. DOI:10.1007/s40261-016-0380-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26951202

3. Wang, M, et al., & Lv, C (2020). Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects. Clinical pharmacology in drug development 9(5) 602–609. DOI:10.1002/cpdd.761 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31823527

Revisions

• 06/2025 initial generated model